These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 25821144)

  • 1. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
    Wang L; Baser O; Kutikova L; Page JH; Barron R
    Support Care Cancer; 2015 Nov; 23(11):3131-40. PubMed ID: 25821144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.
    Cooper KL; Madan J; Whyte S; Stevenson MD; Akehurst RL
    BMC Cancer; 2011 Sep; 11():404. PubMed ID: 21943360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
    Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
    Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
    J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G; Lalla A; Barron R; Dubois RW
    Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
    Pfeil AM; Allcott K; Pettengell R; von Minckwitz G; Schwenkglenks M; Szabo Z
    Support Care Cancer; 2015 Feb; 23(2):525-45. PubMed ID: 25284721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy.
    Schenfeld J; Gong T; Henry D; Kelsh M; Gawade P; Peng Y; Bradbury BD; Li S
    Support Care Cancer; 2022 Jul; 30(7):6327-6338. PubMed ID: 35482126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
    Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
    Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience.
    Cerchione C; De Renzo A; Di Perna M; Della Pepa R; Pugliese N; Catalano L; Pane F; Picardi M
    Support Care Cancer; 2017 Mar; 25(3):839-845. PubMed ID: 27812763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy.
    Wang XJ; Tang T; Farid M; Quek R; Tao M; Lim ST; Wee HL; Chan A
    PLoS One; 2016; 11(2):e0148901. PubMed ID: 26871584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer.
    Aapro MS; Chaplin S; Cornes P; Howe S; Link H; Koptelova N; Mehl A; Di Palma M; Schroader BK; Terkola R
    Support Care Cancer; 2023 Sep; 31(10):581. PubMed ID: 37728795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.
    Link H; Illerhaus G; Martens UM; Salar A; Depenbusch R; Köhler A; Engelhardt M; Mahlmann S; Zaiss M; Lammerich A; Bias P; Buchner A
    Support Care Cancer; 2021 May; 29(5):2519-2527. PubMed ID: 32944800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.
    Morrison VA; Wong M; Hershman D; Campos LT; Ding B; Malin J
    J Manag Care Pharm; 2007 May; 13(4):337-48. PubMed ID: 17506600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015.
    Li S; Liu J; Guo H; Gawade PL; Kim C; Bensink ME; Chandler D
    Support Care Cancer; 2020 Jun; 28(6):2637-2649. PubMed ID: 31624920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy.
    Lyman GH; Reiner M; Morrow PK; Crawford J
    Ann Oncol; 2015 Jul; 26(7):1452-8. PubMed ID: 25851633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.
    Gebremariam GT; Fentie AM; Beyene K; Sander B; Gebretekle GB
    BMC Health Serv Res; 2022 Dec; 22(1):1600. PubMed ID: 36585648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
    Gladkov OA; Buchner A; Bias P; Müller U; Elsässer R
    Support Care Cancer; 2016 Jan; 24(1):395-400. PubMed ID: 26092233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.
    Liu Z; Doan QV; Malin J; Leonard R
    Appl Health Econ Health Policy; 2009; 7(3):193-205. PubMed ID: 19799473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.
    Almenar D; Mayans J; Juan O; Bueno JM; Lopez JI; Frau A; Guinot M; Cerezuela P; Buscalla EG; Gasquet JA; Sanchez J
    Eur J Cancer Care (Engl); 2009 May; 18(3):280-6. PubMed ID: 19076208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.